Latest News and Press Releases

Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program Research Triangle Park, NC, USA and Cambridge, UK, 11 January 2022 -- Inivata, a leader...

Inivata and collaborators to present data that further validate the application of its RaDaR™ MRD and InVisionFirst®-Lung assays at the ESMO Congress 2021 Research Triangle Park, NC, USA and...

Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe ...

Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021 Inivata’s RaDaR® MRD assay performed with exceptionally high sensitivity and...

Inivata’s Liquid Biopsy Technology Included in Unique £10m Research Collaboration for Early Detection of Lung Cancer Research Collaboration to be led by the University of Southampton and along with...

US Commercial Launch of InVisionFirst®-Lung Inivata’s Liquid Biopsy Test for Advanced Non-Small Cell Lung Cancer is Now Available Through NeoGenomics in the US Research Triangle Park, NC, USA and...

Inivata Joins Blood Profiling Atlas in Cancer (BloodPAC) Consortium Research Triangle Park, NC, USA and Cambridge, UK, 18 June 2020 - Inivata, a leader in liquid biopsy, announces that it has...

Inivata and Collaborators to Present New Data from the RaDaR™ Assay at AACR Virtual Annual Meeting II Data will showcase capabilities of newly launched liquid biopsy assay for the detection of...

  Novel approach based on InVision® liquid biopsy platform predicts response to immune checkpoint inhibitors New peer-reviewed publication outlines an approach that identifies NSCLC patients who...

Inivata to Present New Clinical Data on the Utility of Liquid Biopsy and InVisionFirst®-Lung at World Conference on Lung Cancer 2019 Oral presentation and posters to feature Inivata’s...